COVID-19-Associated Hospitalizations Among U.S. Adults Aged ≥18 Years - COVID-NET, 12 States, October 2023-April 2024

Christopher A Taylor,Kadam Patel,Huong Pham,Pam Daily Kirley,Breanna Kawasaki,James Meek,Lucy Witt,Patricia A Ryan,Libby Reeg,Kathy Como-Sabetti,Adrienne Domen,Bridget Anderson,Sophrena Bushey,Melissa Sutton,H Keipp Talbot,Emma Mendez,Fiona P Havers,COVID-NET Surveillance Team,Jeremey Roland,Nisha Alden,Daewi Kim,Kyle P Openo,Maya L Monroe,Val Tellez Nunez,Erica Bye,Dominic Solhtalab,Grant Barney,Christina B Felsen,Nasreen Abdullah,William Schaffner,Isabella Reyes
DOI: https://doi.org/10.15585/mmwr.mm7339a2
2024-10-03
Abstract:Among adults, COVID-19 hospitalization rates increase with age. Data from the COVID-19-Associated Hospitalization Surveillance Network were analyzed to estimate population-based COVID-19-associated hospitalization rates during October 2023-April 2024 and identify demographic and clinical characteristics of adults aged ≥18 years hospitalized with COVID-19. Adults aged ≥65 years accounted for 70% of all adult COVID-19-associated hospitalizations, and their COVID-19-associated hospitalization rates were higher than those among younger adult age groups. Cumulative rates of COVID-19-associated hospitalization during October 2023-April 2024 were the lowest for all adult age groups during an October-April surveillance period since 2020-2021. However, hospitalization rates among all adults aged ≥75 years approached one COVID-19-associated hospitalization for every 100 persons. Among adults hospitalized with COVID-19, 88.1% had not received the 2023-2024 formula COVID-19 vaccine before hospitalization, 80.0% had multiple underlying medical conditions, and 16.6% were residents of long-term care facilities (LTCFs). Guidance for adults at high risk for severe COVID-19 illness, including adults aged ≥65 years and residents of LTCFs, should continue to focus on adopting measures to reduce risk for contracting COVID-19, advocating for receipt of recommended COVID-19 vaccinations, and seeking prompt outpatient antiviral treatment after receipt of a positive SARS-CoV-2 test result.
What problem does this paper attempt to address?